



USD Class I Acc | ISIN: IE00BPRBXQ74

**NAV per Share**

USD Class I Acc US\$19.31

**Fund Details**

Fund Size	US\$115.3 m
Base Currency	USD
Denominations	USD/GBP/EUR
Fund Structure	UCITS
Domicile	Ireland
Listing	Euronext Dublin
Launch Date	12 September 2014
Investment Manager	Polar Capital LLP

**Fund Managers**

**James Douglas**  
 Fund Manager

James has managed the fund since 2019. He joined Polar Capital in 2015 and has 22 years of industry experience.

**Fund Profile**
**Investment Objective**


The Fund aims to achieve long-term capital appreciation by investing in a globally diversified portfolio of healthcare companies.

**Key Facts**

- Team of eight sector specialists
- Team with 175+ years of combined industry experience
- Typically 25-40 large-cap stocks
- No benchmark or tracking error constraints
- Fundamentally-driven analysis and stock selection

**Fund Ratings**


Ratings are not a recommendation. Please see below for further information.

**Share Class Performance**
**Performance Since Launch (%)**


	1m	3m	YTD	1yr	3yrs	5yrs	Since Launch	
							Cum.	Ann.
USD Class I Acc	4.21	-1.58	-1.58	16.54	44.97	73.65	93.10	9.10
Index	4.60	-3.79	-3.79	12.56	47.49	79.62	98.35	9.49

**Discrete Annual Performance (%)**

12 months to	31.03.22	31.03.21	31.03.20	29.03.19	29.03.18
USD Class I Acc	16.54	33.20	-6.61	12.69	6.29
Index	12.56	30.21	0.64	10.95	9.77

**Performance relates to past returns and is not a reliable indicator of future returns.**

Performance for the USD Class I Acc. The class launched on 12 September 2014. Performance data is shown in USD. Source: Northern Trust International Fund Administration Services (Ireland) Ltd. Benchmark performance shown in USD. Source: Bloomberg.

If this is not your local currency, exchange rate fluctuations may cause performance to increase or decrease when converted into your local currency.

Performance data takes account of fees paid by the fund but does not take account of any commissions or costs you may pay when subscribing for or redeeming shares or any taxes or securities account charges that you may pay on your investment in the fund. Such charges will reduce the performance of your investment.

## Portfolio Exposure & Attribution

As at 31 March 2022

### Top 10 Positions (%)

Johnson & Johnson	8.2
UnitedHealth Group	7.5
Bristol Myers Squibb	4.9
Sanofi	4.5
Steris	3.5
Boston Scientific Corp	3.4
Horizon Pharma	3.2
Alcon	3.2
Bio-Rad Laboratories	3.1
Zimmer Biomet Holdings	2.9

**Total** 44.5

**Total Number of Positions** 34

**Active Share** 75.68%

### Geographic Exposure (%)

United States	68.9
Germany	5.2
Japan	4.8
France	4.5
Switzerland	3.2
United Kingdom	2.9
Netherlands	2.3
Belgium	2.3
Sweden	2.0
Denmark	1.4
Cash	2.5

### Market Capitalisation Exposure (%)

Large Cap (>US\$10 bn)	80.2
Mid Cap (US\$5 bn - 10 bn)	17.3
Small Cap (<US\$5 bn)	0.0
Cash	2.5

### Performance Attribution - 1 Month (%)

#### Top Contributors

	Active Weight	Attrib. Effect
Horizon Pharma	3.21	0.34
Acadia Healthcare	2.38	0.30
Swedish Orphan Biovitrum AB	1.26	0.23
Seattle Genetics	2.37	0.15
UCB	2.44	0.13


#### Top Detractors

	Active Weight	Attrib. Effect
Bio-Rad Laboratories	2.93	-0.46
Baxter International	2.21	-0.31
Eli Lilly & Co	-2.93	-0.27
AptarGroup	2.49	-0.23
Astellas Pharma	2.04	-0.22

Performance attribution is calculated in USD on a relative basis over the month.

### Sector Exposure - Top Overweights & Underweights Relative to Index (%)

	Fund	Relative
Pharmaceuticals	27.6	-11.4
Healthcare Equipment	22.4	3.3
Biotechnology	17.2	4.0
Managed Healthcare	8.9	-0.5
Healthcare Facilities	6.4	4.9
Life Sciences Tools & Services	5.8	-3.0
Healthcare Technology	3.2	1.6
Healthcare Supplies	2.4	0.2
Metal & Glass Containers	2.1	2.1
Healthcare Services	1.5	-2.4
Healthcare Distributors	0.0	-1.5
Cash	2.5	2.5



The column headed "Fund" refers to the percentage of the Fund's assets invested in each sector. The column headed "Relative" refers to the extent to which the Fund is overweight or underweight in each sector compared (relative) to the index.

Note: Totals may not sum due to rounding. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

## Share Class Information

Share Class	Bloomberg	ISIN	SEDOL	Minimum Investment	OCF <sup>†</sup>	Ann. Fee	Perf. Fee <sup>††</sup>
USD I Acc	PCFIUSA ID	IE00BPRBXQ74	BPRBXQ7	-	0.96%	0.85%	10%
USD I Dist	PCFIUSD ID	IE00BPRBXP67	BPRBXP6	-	0.96%	0.85%	10%
GBP I Acc	PCFIGBA ID	IE00BPRB XV28	BPRB XV2	-	0.96%	0.85%	10%
GBP I Dist	PCFIGBD ID	IE00BPRB XT06	BPRB XT0	-	0.96%	0.85%	10%
EUR I Acc	PCFIEUA ID	IE00BPRB XS98	BPRB XS9	-	0.96%	0.85%	10%
EUR I Dist	PCFIEUD ID	IE00BPRB XR81	BPRB XR8	-	0.96%	0.85%	10%

<sup>†</sup>Ongoing Charges Figure (OCF) is the latest available, as per the date of this factsheet.

<sup>††</sup>Performance Fee 10% of outperformance of MSCI World Daily Total Return Net Health Care Index.

## Fund Manager's Comments

Despite the global challenges, March was a positive month for global equities, with the healthcare sector outperforming the broader market. From a healthcare subsector perspective, pharmaceuticals, biotechnology, managed care and distributors all experienced strong returns, while healthcare supplies and services, life sciences tools and services, healthcare equipment and healthcare facilities exhibited a more muted performance. The Fund was up 4.2% (I US\$ Acc Share Class) in March, modestly lagging the benchmark (MSCI AC World Daily Net TR Health Care Index) which increased by 4.6% (in dollar terms).

### Macro backdrop

The Russian offensive into Ukraine continued into March, with hopes for a swift resolution vanishing after numerous inconclusive meetings between the various parties. The global community responded to the invasion by imposing further sanctions on Russia and Belarus, sanctions that are already starting to impact international businesses. Furthermore, commodities, especially oil, agricultural products and certain metals, continued the upwards trajectory that started in late February, given the importance of both countries in their production. These price increases only add more fuel to the already rampant inflationary fire. Understandably, investors accelerated their retreat into safe havens and more defensive sectors.

Many countries have seen a resurgence of COVID-19 cases, with Asia-Pacific especially impacted. We believe this may be due to a combination of less effective vaccines, lower vaccine uptake and lower acquired immunity. China is one example of a government responding quickly to the higher number of infections by forcing cities into full lockdown, including Shanghai, one of the busiest container ports in the world. These lockdowns have further weakened an already fragile global supply chain with many companies warning they might be unable to fulfil orders because some components are unavailable, their factories are shut or they are unable to ship goods.

The disruption of the delivery of healthcare is a key investment theme for the Polar Capital healthcare team, as is the need for effective behavioural health services. During March, the US healthcare insurance and services company UnitedHealth Group invested in both areas, underpinning our view that both opportunities are increasing in importance and offer sustainable growth. They first acquired outpatient mental health provider Refresh Mental Health and then home-health provider LHC Group. In both instances, UnitedHealth Group is looking to improve care coordination, improve outcomes and patient experiences as well as drive better value.

### Fund activity

Positive contributors during the reporting period included Horizon Pharma, Acadia Healthcare and Swedish Orphan Biovitrum. Horizon Pharma produced a strong set of FY21 financial results coupled with encouraging FY22 guidance. The company's drug development news flow also continues to be positive. Acadia Healthcare also disclosed a solid set of FY21 results coupled with FY22 guidance that offered relief in the face of nervousness around staff recruitment and wage inflation. Swedish Orphan Biovitrum, a recent addition to the portfolio, published positive clinical data in the field of haemophilia A, potentially offering long-term sustainability for one of its key franchises.

Negative contributors in March were Bio-Rad Laboratories, Baxter International and Eli Lilly & Co. There was no company-specific news flow for Bio-Rad Laboratories during the period, with the stock continuing to struggle alongside its life sciences tools and services peers. With regards Baxter International, the market is concerned

about the company's freight costs, input costs and access to semiconductors for its smart beds and dialysis businesses. The Fund's lack of exposure to Eli Lilly & Co. hurt performance, with the stock performing well alongside a number of its large-cap pharmaceutical peers.

We used some of the uncertainty in the market to increase our exposure to the biotechnology and pharmaceuticals subsectors with the additions of Chugai Pharmaceuticals, Incyte Corporation and Swedish Orphan Biovitrum, all of which appear to have positive momentum with existing launches as the market recovers from the COVID-19 pandemic. We also added life sciences tools and services company Sartorius which we believe to be a high-quality operator in end markets with attractive growth prospects. Sales in Abbott Laboratories and Alnylam Pharmaceuticals funded the purchases.

Despite the cocktail of rising inflation, more hawkish central banks and war in eastern Europe, the markets remain incredibly resilient. Importantly, however, we believe the risks of slowing economic activity and/or a recession have not disappeared completely, both of which are scenarios that make the healthcare sector look more attractive on a relative basis. That appeal is heightened further if one takes the view that the utilisation and consumption of healthcare products and services will pick-up as COVID-19 moves away from being a pandemic and becomes more endemic in nature. If that is the case, we could see upwards pressure on revenues for a broad swathe of healthcare companies as we navigate our way through the year.

James Douglas

4 April 2022

## Risks

- Capital is at risk and there is no guarantee the Fund will achieve its objective. Investors should make sure their attitude towards risk is aligned with the risk profile of the Fund.
- Past performance is not a reliable guide to future performance. The value of investments may go down as well as up and you might get back less than you originally invested.
- The value of a fund's assets may be affected by uncertainties such as international political developments, market sentiment, economic conditions, changes in government policies, restrictions on foreign investment and currency repatriation, currency fluctuations and other developments in the laws and regulations of countries in which investment may be made. Please see the Fund's Prospectus for details of all risks.
- The Fund may enter into a derivative contract. The Fund's use of derivatives carries the risk of reduced liquidity, substantial loss and increased volatility in adverse market conditions, such as failure amongst market participants.
- The use of derivatives will result in the Fund being leveraged (where market exposure and the potential for loss exceeds the amount the Fund has invested) and in these market conditions the effect of leverage will magnify losses. The Fund makes extensive use of derivatives.
- If the currency of the share class is different from the local currency in the country in which you reside, the figures shown in this document may increase or decrease if converted into your local currency.

## Important Information

This is a marketing communication and does not constitute a solicitation or offer to any person to buy or sell and related securities or financial instruments. Any opinions expressed may change. This document does not contain information material to the investment objectives or financial needs of the recipient. This document is not advice on legal, taxation or investment matters. Tax treatment depends on personal circumstances. Investors must rely on their own examination of the fund or seek advice. Investment may be restricted in other countries and as such, any individual who receives this document must make themselves aware of their respective jurisdiction and observe any restrictions.

A decision may be taken at any time to terminate the marketing of the Fund in any EEA Member State in which it is currently marketed. Shareholders in the affected EEA Member State will be given notification of any decision and provided the opportunity to redeem their interests in the Fund, free of any charges or deductions, for at least 30 working days from the date of the notification.

Further information and any associated risks can be found in the Fund's Key Investor Information Document ("KIID"), the Prospectus, the Articles of Association and the annual and semi-annual reports. These documents are available free of charge at Polar Capital Funds PLC, Georges Court, 54-62 Townsend Street, Dublin 2, via email by contacting [Investor-Relations@polarcapitalfunds.com](mailto:Investor-Relations@polarcapitalfunds.com) or at [www.polarcapital.co.uk](http://www.polarcapital.co.uk). The KIID is available in Danish, Dutch, English, French, German, Italian, Spanish and Swedish; the Prospectus is available in English.

A summary of investor rights associated with investment in the Fund is available online at the above website, or by contacting the above email address.

In the United Kingdom and Switzerland, this document is provided and approved by Polar Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA"). Registered address: 16 Palace Street, London SW1E 5JD. Polar Capital LLP is a registered investment adviser with the United States' Securities and Exchange Commission ("SEC"). Polar Capital LLP is the investment manager and promoter of Polar Capital Funds PLC – an open-ended investment company with variable capital and with segregated liability between its sub-funds – incorporated in Ireland, authorised by the Central Bank of Ireland and recognised by the FCA. Bridge Fund Management Limited acts as management company and is regulated by the Central Bank of Ireland. Registered Address: Ferry House, 48-53 Mount Street Lower, Dublin 2, Ireland.

**Benchmark** The Fund is actively managed and uses the MSCI AC World Daily Total Return Net Health Care Index as a performance target and to calculate the performance fee. The benchmark has been chosen as it is generally considered to be representative of the investment universe in which the Fund invests. The performance of the Fund is likely to differ from the performance of the benchmark as the holdings, weightings and asset allocation will be different. Investors should carefully consider these differences when making comparisons. Further information about the benchmark can be found [www.msccibarra.com](http://www.msccibarra.com). The benchmark is provided by an administrator on the European Securities and Markets Authority (ESMA) register of benchmarks which includes details of all authorised, registered, recognised and endorsed EU and third country benchmark administrators together with their national competent authorities.

## Administrator Details

Northern Trust International Fund Administration Services (Ireland) Ltd

Telephone	+ (353) 1 434 5007
Fax	+ (353) 1 542 2889
Dealing	Daily
Cut-off	15:00 Irish time

**Country Specific Disclaimers** Please be aware that not every share class of every fund is available in all jurisdictions. When considering an investment into the Fund, you should make yourself aware of the relevant financial, legal and tax implications. Neither Polar Capital LLP nor Polar Capital Funds plc shall be liable for, and accept no liability for, the use or misuse of this document.

**The Netherlands** This factsheet is for professional client use only in the Netherlands and it is intended that the Fund will only be marketed to professional clients in the Netherlands. Polar Capital Funds plc is authorized to offer shares in the Polar Capital Funds plc - Healthcare Blue Chip Fund to investors in the Netherlands on a cross border basis and is registered as such in the register kept by the Dutch Authority for the Financial Markets ("AFM") [www.afm.nl](http://www.afm.nl).

**Spain** The Fund is registered in Spain with the Comisión Nacional del Mercado de Valores ("CNMV") under registration number 771.

**Switzerland** The principal fund documents (the prospectus, KIIDs, memorandum and articles of association, annual report and semi-annual report) of the Fund may be obtained free of charge from the Swiss Representative. The Fund is domiciled in Ireland. The Swiss representative and paying agent is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, CH-8002 Zurich, Switzerland.

**Austria / Denmark (professional only) / Finland / Germany / Ireland / Italy (professional only) / Luxembourg / Norway / Spain / Sweden and the United Kingdom** The Fund is registered for sale to all investors in these countries. Investors should make themselves aware of the relevant financial, legal and tax implications if they choose to invest.